Psychiatric Times May 5, 2024
This 2024 APA Annual Meeting poster investigated the relationship between antiobesity agents like semaglutide and depression.
CONFERENCE REPORTER
Semaglutide, a glucagon-like peptide-1 (GLP-1) analog approved for the treatment of type 2 diabetes, was also approved in the US, Europe, the UK, and Canada in once-weekly subcutaneous formulation for weight management in overweight adults with at least 1 weight-related comorbidity and obesity. The only other GLP-1 analog approved for obesity by the FDA, liraglutide, regulates appetite via action on the hypothalamus. While no significant psychiatric adverse effects have been reported with semaglutide compared with placebo thus far, psychiatric adverse effects, including suicidal ideation, have been reported with other GLP-1 receptor agonists.
Presented at the 2024 American Psychiatric Association Annual Meeting, the...
Today's Sponsors
Today's Sponsor